A Membrane Fluidization Strategy Significantly Boosts Photodynamic Therapy and Antitumor Immunity of Porphyrin-Lipid Nanoparticles

Porphysomes (PS) are self-assembled porphyrin-lipid nanoparticles with intrinsic multifunctionality for cancer theranostics. We recently discovered that incorporating EDTA-conjugated lipids (EDTA-lipids) into lipid nanoparticle formulations significantly enhances intracellular uptake by modulating the cell membrane fluidity. To retain the favorable <i>in vivo</i> properties of PS while improving intracellular porphyrin delivery for effective photodynamic therapy (PDT), we developed a dual cellular- and vascular-enriched porphysome (DE-PS) containing 30 mol % cholesterol, 5 mol % PEG2000-DSPE, 27 mol % pyro-lipid, and 38 mol % EDTA-lipid. DE-PS demonstrated favorable pharmacokinetics (<i>t</i> <sub><sub>1</sub>/<sub>2</sub>β</sub> = 7.5 h), robust photostability (>99% fluorescence quenching), and strong serum stability over 24 h (>85% fluorescence quenching retained). Compared to PS, DE-PS resulted in an 11-fold increase in KB cancer cell uptake and achieved >95% PDT-induced cell death, in contrast to <5% with PS. Intravital imaging showed enhanced intratumoral porphyrin activation in DE-PS-treated mice, with stronger fluorescence signals observed in tumor vasculature and necrotic regions, leading to superior <i>in vivo</i> PDT efficacy across all drug-light-intervals. Notably, while low-dose PDT (25 J/cm<sup>2</sup>) with DE-PS had minimal impact on CT-26 tumor growth in immunodeficient NSG mice, it resulted in marked tumor suppression and prolonged survival in immunocompetent BALB/c mice, highlighting the importance of PDT-induced immune activation in the therapeutic response. A single DE-PS PDT treatment led to durable tumor-free survival exceeding 90 days. Upon CT-26 tumor rechallenge, previously cured mice rejected tumor regrowth, demonstrating development of long-lasting immunity without utilizing additional immunostimulants. This study highlights DE-PS as a promising next-generation porphysome-based photosensitizer platform for effective cancer phototherapy and immune modulation.

Authors

Institutions

Publication Details

Journal
ACS Nano Medicine
Published
2025-10-16
DOI
https://doi.org/10.1021/acsnanomed.5c00053
Citations
1
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Membrane Fluidization Strategy Significantly Boosts Photodynamic Therapy and Antitumor Immunity of Porphyrin-Lipid Nanoparticles

Keegan Guidolin, Tiffany Ho, Yulin Mo, Tracy Liu et al.
1 citations
ACS Nano Medicine
Nanoplatforms for cancer theranostics
0.67
article

A Membrane Fluidization Strategy Significantly Boosts Photodynamic Therapy and Antitumor Immunity of Porphyrin-Lipid Nanoparticles

Keegan Guidolin, Tiffany Ho, Yulin Mo, Tracy Liu, Ali Makky, Mark Zheng, Nahyun Kwon, Michael S. Valic, Lili Ding, Gang Zheng, Brian C. Wilson, Layla Pires, Juan Chen, Yiming Yang, Ashley Qian
article en
1 citations

Abstract

Porphysomes (PS) are self-assembled porphyrin-lipid nanoparticles with intrinsic multifunctionality for cancer theranostics. We recently discovered that incorporating EDTA-conjugated lipids (EDTA-lipids) into lipid nanoparticle formulations significantly enhances intracellular uptake by modulating the cell membrane fluidity. To retain the favorable <i>in vivo</i> properties of PS while improving intracellular porphyrin delivery for effective photodynamic therapy (PDT), we developed a dual cellular- and vascular-enriched porphysome (DE-PS) containing 30 mol % cholesterol, 5 mol % PEG2000-DSPE, 27 mol % pyro-lipid, and 38 mol % EDTA-lipid. DE-PS demonstrated favorable pharmacokinetics (<i>t</i> <sub><sub>1</sub>/<sub>2</sub>β</sub> = 7.5 h), robust photostability (>99% fluorescence quenching), and strong serum stability over 24 h (>85% fluorescence quenching retained). Compared to PS, DE-PS resulted in an 11-fold increase in KB cancer cell uptake and achieved >95% PDT-induced cell death, in contrast to <5% with PS. Intravital imaging showed enhanced intratumoral porphyrin activation in DE-PS-treated mice, with stronger fluorescence signals observed in tumor vasculature and necrotic regions, leading to superior <i>in vivo</i> PDT efficacy across all drug-light-intervals. Notably, while low-dose PDT (25 J/cm<sup>2</sup>) with DE-PS had minimal impact on CT-26 tumor growth in immunodeficient NSG mice, it resulted in marked tumor suppression and prolonged survival in immunocompetent BALB/c mice, highlighting the importance of PDT-induced immune activation in the therapeutic response. A single DE-PS PDT treatment led to durable tumor-free survival exceeding 90 days. Upon CT-26 tumor rechallenge, previously cured mice rejected tumor regrowth, demonstrating development of long-lasting immunity without utilizing additional immunostimulants. This study highlights DE-PS as a promising next-generation porphysome-based photosensitizer platform for effective cancer phototherapy and immune modulation.

ACS Nano MedicineVol. 1(1)
West Virginia University (US), Centre National de la Recherche Scientifique (FR), University of Toronto (CA), Université Paris-Saclay (FR), Cancer Institute (WIA) (IN), Mitchell Institute (US), Princess Margaret Cancer Centre (CA), West Virginia State University (US), Texas A&M University (US)
Openalex Percentile: Top 26%
Nanoplatforms for cancer theranostics
0.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.